122M

Cardiovascular Disease Patients in US[1]



50%

of all Cardiovascular Disease patients suffer from sleep apnea[2]



85%

of all obstructive sleep apnea patients remain undiagnosed[2]

Sleep apnea impacts your patients' health



2x Increased risk of stroke[3]

Sleep apnea impacts your patients' health



2x Risk of death from sudden cardiac arrest[4]

Sleep apnea impacts your patients' health



5x Risk of death from cardiovascular disease[5]

Sleep apnea impacts your patients' health



42%

Increased risk of recurrence of AF following ablation[6]

The American Heart Association recommends…[7]

American Heart Association.

Screening for OSA if…

- ✓ Resistant/poorly controlled hypertension
- ✓ Pulmonary hypertension
- ✓ Recurrent atrial fibrillation (after either cardioversion or ablation)

A sleep study if…

- ✓ NYHA class II–IV HF symptoms
- ✓ Tachy-brady syndrome
- ✓ Sick sinus syndrome
- ✓ Ventricular tachycardia
- ✓ Survivors of sudden cardiac death
- ✓ Stroke

Learn how ZOLL is helping cardiologists manage patients with sleep apnea

WatchPAT®

remedē® System

References

[1] Virani, S. Alonso, A. Benjamin, E. et al. Heart Disease and Stroke Statistics – 2020 Update. *Circulation* 2020; 141:00-00 ePub.

[2] Somers VK, White D, Amin R. et al. Sleep apnea and cardiovascular disease: An AHA/ACCF Scientific Statement. *JACC* Vol. 52, No. 8, 2008, August 19, 2008:686–717.

[3] Redline S, Yenokyan G, Gottlieb DJ, et al, Obstructive sleep apnea and incident stroke: The sleep heart health study. *Am J Resp Crit Care Med*. 2010; 182(2);269-277.

[4] Gami AS, Olson EJ, Shen WK, et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10701 adults. *J Am Coll Cardiol* 2013; 62(7);610-6.

[5] Young T, Finn L, Peppard PE, et al. Wleep disordered breathing and mortality: Eighteen year follow up of the Wisconsin sleep cohort. *Sleep* 2008; Aug 1;31(8):1071-1078.

[6] Shukla A, Aizer A, Holmes D, et al. Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence: A Meta-Analysis. *JACC: Clinical Electrophysiology* March 2015;1(1-2):41-51.

[7] Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, Mehra R, Bozkurt B, Ndumele CE, Somers VK. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-e67. doi: 10.1161/CIR.0000000000000988. Epub 2021 Jun 21. Erratum in: Circulation. 2022 Mar 22;145(12):e775. PMID: 34148375.

Important Safety Information

The **rem**edē® System is indicated for moderate to severe Central Sleep Apnea (CSA) in adult patients. A doctor will need to evaluate the patient's condition to determine if the **rem**edē System is appropriate. Patients will not be able to have an MRI or diathermy (special heat therapies) if the **rem**edē System is implanted. The **rem**edē System may be used with another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting. As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection. Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The **rem**edē System may not work for everyone. There are additional risks associated with removing the system. If it is decided to remove the system, another surgery will be required. Be sure to understand all of the risks and benefits associated with the implantation of the **rem**edē System. For further information please visit remede.zoll.com, call 952-540-4470 or email info@remede.zoll.com. **Indication for use**: The **rem**edē System is an implantable phrenic nerve stimulator indicated for the treatment of moderate to severe Central Sleep Apnea (CSA) in adult patients. **Contraindications**: The **rem**edē System is contraindicated for use in patients with an active infection or patients known to require magnetic resonance imaging (MRI). See the Instructions for Use for complete information regarding the procedure, indications for use, contraindications, warnings, precautions, and potential adverse events.
Rx Only.

The **rem**edē® System, **rem**edē® EL System, and **rem**edē® EL-X System have received FDA approval. The **rem**edē® System model 1001 has received CE Mark approval.

ZOLL®